Abstract: Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and ?-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Abstract: A shaver is proposed. The shaver may include a handle for gripping by a user, a power generation unit, attached to the handle, for generating rotational power, and a power transmission unit which rotates by means of the rotational power. The shaver may also include a cartridge comprising a blade housing in which one or more blades are seated, and a power reception unit, on one surface of the cartridge so as to allow contact with the power transmission unit, for moving the blade housing linearly in accordance with the rotation of the power transmission unit. The cartridge may be coupled to the handle so as to allow pivoting around the pivot axis which is perpendicular to the rotational axis of the rotational power generated by the power generation unit, and the pivot axis may be established so as to penetrate the power transmission unit.

Abstract: Provided is a genome extraction device to which a dual chamber structure of an outer chamber and an inner chamber is applied, more particularly a genome extraction device to which the above-described dual chamber structure is applied so that the genome extraction device can be stored stably for a long time without the risk of reagent leakage.

Abstract: According to various embodiments of the present invention, disclosed is an electronic device comprising: a first antenna element configured so as to transmit and receive a signal of a first frequency band or a second frequency band; a second antenna element configured so as to transmit and receive the signal of the first frequency band or the second frequency band; a first RF block electrically connected to the first antenna element and the second antenna element and including a first transmission and reception circuit and a second transmission and reception circuit; an RF reception circuit for receiving the signal of the first frequency band or the second frequency band from the first antenna element or the second antenna element; and a transceiver, wherein the first transmission and reception circuit processes the signal of the first frequency band or the second frequency band, the second transmission and reception circuit processes the signal of the first frequency band or the second frequency band, and th

Abstract: A medical dressing includes: a lower support film; a release film; and an adhesive sheet part (110) for application, which is placed on the release film (200) and is attached to the skin, wherein the release film (200) consists of a release film part (210) for fixing and a separable release film part (220) to be separated therefrom by a cutting line (211) formed on the release film part (210) for fixing, so that a predetermined region of the separable release film part is positioned to overlap with the bottom surface of the adhesive sheet part (110), thereby allowing, during separation of the separable release film part (220) from the release film part (210) for fixing, separation together with the adhesive sheet part (110) for application, and the area of the separable release film part (220), which overlaps with the bottom surface of the adhesive sheet part (110), is relatively smaller than the area of the separable release film part, which does not overlap with the adhesive sheet part (110).

Abstract: A semiconductor device a strapped interconnect line, which in turn includes a first interconnect line at a first level above a semiconductor substrate, and a second interconnect line at a second level above the interconnect substrate. A dielectric capping layer is located directly on the first interconnect line. A plurality of strapping vias are connected between the first interconnect line and the second interconnect line. Each of the strapping vias extends from a first side of the first interconnect line to a second side of the second interconnect line.

Abstract: Ophthalmic therapeutic agents having as pharmaceutically active ingredient a poorly water soluble drug of formula 1 are described. Specifically, an ophthalmic formulation containing an inclusion complex of a poorly soluble drug of formula 1 enclosed in cyclodextrin or a cyclodextrin derivative in an aqueous solution of pH 10 or higher is administered to a patient in need of optic nerve protection.

Abstract: The present invention relates to a novel cocrystal, a pharmaceutical composition comprising same and a preparation method therefor. By using the cocrystal of the present invention, cancers, inflammatory diseases, or viral infection diseases may be effectively prevented and/or treated.

Abstract: The present invention relates to a liquid crystalline structure-forming omega-3-fatty acid composition and, more specifically, provides an omega-3-fatty acid composition comprising: amphoteric lipids which form liquid crystalline structures when exposed to aqueous media such as gastrointestinal juice; omega-3 fatty acids or derivatives thereof; and a liquid crystalline structure-forming aid. The omega-3-fatty acid composition forms self-assembled lyotropic liquid crystals which are thermodynamically stable in structure, irrespective of digestion in the gastrointestinal tract, thereby promoting the solubilization and absorption rate of omega-3-fatty acids as well as providing preparations 30% or more smaller in size than conventional soft gel capsules of omega-3-fatty acid preparations. Thus, the composition can be taken with more ease by geriatric patients and the like and allows for provision of omega-3-fatty acid preparations increasing in in-vivo dissolution and absorption.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.

Abstract: A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.

Abstract: Disclosed herein are an emergency operating system and an emergency operating method for a hybrid vehicle with a damaged bearing of an engine, which are capable of preventing a bearing from being further damaged due to a drive motor and a hybrid starter and generator (HSG) when damage to the bearing installed in an engine is detected and capable of driving the hybrid vehicle and which include a bearing damage detection operation, an engine driving maintaining operation, a first state of charge (SOC) comparison operation, and a first emergency operating operation.

Abstract: The present invention relates to a composition comprising a bilberry extract as an active ingredient for preventing or treating sensorineural hearing impairment. The bilberry extract was found to exhibit effects of inhibiting the apoptosis of auditory cells in which sensorineural damage has been induced by neomycin and increasing a reduced number of hair cells in juvenile zebra fishes such that the composition comprising the bilberry extract as an active ingredient can be provided as a pharmaceutical composition and a health food for preventing or treating various hearing impairments induced by sensorineural damage.

Abstract: A method for sensing damage to a bearing of an engine using a vibration signal may sense the damage to the bearing even without a sensor for directly sensing the damage to the bearing using a frequency signal input to a knocking sensor from the engine for each traveling state (acceleration traveling, cruise traveling, deceleration traveling) of a vehicle.

Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Abstract: A method for sensing damage to a bearing of an engine using a vibration signal may sense the damage to the bearing even without a sensor for directly sensing the damage to the bearing using a frequency signal input to a knocking sensor from the engine for each traveling state (acceleration traveling, cruise traveling, deceleration traveling) of a vehicle.

Abstract: The present invention relates to a medical dressing and a manufacturing method, and to a medical dressing and a manufacturing method therefor, the medical dressing comprising: a lower support film; a release film; and an adhesive sheet part (110) for application, which is placed on the release film (200) and is attached to the skin, wherein the release film (200) consists of a release film part (210) for fixing and a separable release film part (220) to be separated therefrom by a cutting line (211) formed on the release film part (210) for fixing, so that a predetermined region of the separable release film part is positioned to overlap with the bottom surface of the adhesive sheet part (110), thereby allowing, during separation of the separable release film part (220) from the release film part (210) for fixing, separation together with the adhesive sheet part (110) for application, and the area of the separable release film part (220), which overlaps with the bottom surface of the adhesive sheet part (110)

Abstract: Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and ?-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.